Carolus Therapeutics, Inc. is a biopharmaceutical company committed to the development of innovative new drugs that will provide relief to patients suffering from a host of disorders triggered by acute and chronic inflammation. The clinical and commercialization focus of the company is on novel therapeutic strategies to noninvasively monitor and disrupt proinflammatory interactions of chemokines and prevent or reverse inflammation associated with a broad array of human diseases. The company’s patented technology represents a promising advance in inflammation therapy where the underlying disease, as opposed to the symptoms, is treated without significant side effect profiles.


Carolus’ technology and intellectual property has enabled modality-independent development of therapeutic peptides and antibodies that target specific interactions between MIF and its chemokine receptors, and RANTES and platelet factor-4.


Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice.
Nature Medicine, Jan 2009